Olmesartan medoxomil-based therapy for the management of hypertension

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Current hypertension guidelines recommend specific blood pressure (BP) goals: <140/90 mmHg for general hypertension and <130/80 mmHg for patients with diabetes or chronic kidney disease.
• Achieving these BP goals often necessitates combination therapy with agents possessing complementary mechanisms of action.

Purpose of the Study:

• To review the chemistry, efficacy, and safety of olmesartan medoxomil-based therapies for hypertension management.
• To evaluate the expanding role of olmesartan medoxomil in diverse patient populations.

Main Methods:

• Review of existing literature, including large, randomized clinical trials.
• Evaluation of olmesartan medoxomil's efficacy and safety in monotherapy and combination therapy.

Main Results:

• Olmesartan medoxomil, an angiotensin receptor blocker, demonstrates good BP-lowering efficacy and goal attainment in stage 1 and 2 hypertension.
• Established comparative antihypertensive efficacy and safety profiles for olmesartan medoxomil in various treatment regimens.

Conclusions:

• Olmesartan medoxomil-based therapy is effective for managing hypertension across different patient types.
• Combination therapy with olmesartan medoxomil is a valuable strategy for achieving target blood pressure goals.